SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
复制标题
玻璃体内注射雷珠单抗或康柏西普治疗新生血管性年龄相关性黄斑变性前后血清血管内皮生长因子水平
DOI：
10.1097/iae.0000000000001274
复制
发表时间：
2017-05-01
影响因子：
3.3
通讯作者：
Zhao, Mingwei
中科院分区：
文献类型：
--
作者：
Jin, Enzhong;Bai, Yujing;Zhao, Mingwei
目的：探讨玻璃体内注射康柏西普或雷珠单抗治疗新生血管性年龄相关性黄斑变性和息肉状脉络膜血管pathology.Methods：本研究是一项前瞻性的干预性病例系列，涉及28例患者，18例用0.5 mg康柏西普治疗，10例用0.5 mg雷珠单抗治疗。在注射前和抗VEGF治疗后1天、1周和1个月，通过酶联免疫吸附测定法测定血清VEGF浓度。结果：雷珠单抗组的基线血清VEGF水平为367.11 +/- 311.87 pg/mL，而康柏西普组为315.06 +/- 170.88 pg/mL（P = 0.653）。在康柏西普组中，VEGF水平在第1天显著降低至36.32 +/- 72.11 pg/mL（P = 0.03），并在第1周恢复至136.55 +/- 144.62 pg/mL（P = 0.03）。1个月时，浓度增加至334.48 +/- 197.41 pg/mL，与基线相比无显著差异。在雷珠单抗组中，玻璃体内注射后1天、1周和1个月的血清VEGF水平分别为292.42 +/- 239.80 pg/mL、282.60 +/- 201.36 pg/mL和308.83 +/- 266.89 pg/mL。结论：康柏西普注射后1 d和1周可显著降低血清VEGF水平，但这种作用不能持续1个月。相反，雷珠单抗对血清VEGF浓度变化无显著影响。Conbercept降低血清VEGF可能影响其全身安全性特征。
Objective: To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients.Methods: This study is a prospective, interventional case series and involved 28 patients, 18 treated with 0.5 mg of conbercept and 10 treated with 0.5 mg of ranibizumab. Serum concentrations of VEGF were determined by enzyme-linked immunosorbent assay before the injection and at 1 day, 1 week, and 1 month after anti-VEGF treatments.Results: The baseline serum VEGF level of the ranibizumab group was 367.11 +/- 311.87 pg/mL, whereas that of the conbercept group was 315.06 +/- 170.88 pg/mL (P = 0.653). In the conbercept group, VEGF level significantly decreased to 36.32 +/- 72.11 pg/mL at 1 day (P = 0.03) and returned to 136.55 +/- 144.62 pg/mL at 1 week (P = 0.03). At 1 month, the concentration increased to 334.48 +/- 197.41 pg/mL and showed no significant difference compared with the baseline. In the ranibizumab group, the serum VEGF levels were 292.42 +/- 239.80 pg/mL, 282.60 +/- 201.36 pg/mL, and 308.83 +/- 266.89 pg/mL at 1 day, 1 week, and 1 month after intravitreal injection, respectively. There was no significant difference in the ranibizumab group at each detection time point (P = 0.45).Conclusion: Conbercept significantly decreased serum VEGF level 1 day and 1 week after injection, but this effect was not sustained for 1 month. In contrast, ranibizumab had no significant effect on serum VEGF concentration changes. The reduction in serum VEGF by conbercept may affect its systemic safety profile.